Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients

Conclusions Our data suggest that disease reactivation peaked during a “high risk period” between the second and the eighth month since stopping the drug. During this period no alternative treatments seemed to provide an adequate protection from disease reactivation. Though transient, this phase could be potentially dangerous, therefore we need to develop more effective strategies to deal with this challenge.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research